8-K: Kairos Pharma Secures Investor Relations Partner, Stockholders Approve Key Governance Measures Including Potential Dilutive Share Issuance

Kairos Pharma, Ltd. announced the engagement of Barretto Pacific Corporation for investor relations services and reported the results of its annual stockholders' meeting, where all director nominees were elected and a significant authorization for future share issuance below minimum price was approved.

Summary

• Kairos Pharma, Ltd. (KAPA) entered into a one-year services agreement with Barretto Pacific Corporation (BPC) effective June 10, 2025, for investor relations services.
• BPC will receive a fee of $170,000, paid in monthly increments, for services including public information dissemination, communication with the investment community, arranging investor conferences, and reviewing news releases.
• The company held its annual meeting of stockholders on June 10, 2025, where four director nominees (John S. Yu, M.D., Hyun W. Bae, M.D., Hansoo Michael Keyoung, M.D., Ph.D., and Rahul Sighvi, Sci.D., MBA) were elected for a one-year term.
• Stockholders ratified the appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The company's executive compensation was approved on an advisory basis, and stockholders also approved conducting advisory votes on executive compensation annually.
• A significant resolution was passed, approving the issuance of in excess of 20% of the company's common stock at a price below minimum price, in compliance with NYSE American LLC Company Guide Section 713.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While securing investor relations services and maintaining stable governance are positive, the approval of a potentially dilutive share issuance below minimum price introduces a significant negative factor for existing shareholders.

Positives

• The engagement of Barretto Pacific Corporation is expected to enhance Kairos Pharma's visibility and communication within the investment community, potentially attracting new investors.
• The successful election of all director nominees and ratification of the independent auditors indicates stable corporate governance and shareholder confidence in the current leadership and oversight.
• Stockholders' approval of executive compensation and the annual frequency for future votes demonstrates alignment between management and shareholders on compensation practices.

Negatives

• The approval to issue more than 20% of common stock at a price below the minimum price could lead to significant dilution for existing shareholders, potentially impacting share value.

Risks

• Potential dilution of existing shareholder value due to the approved authorization to issue a substantial percentage of common stock below the minimum price.
• Reliance on Barretto Pacific Corporation for investor relations services, with the effectiveness of these services impacting market perception and investor interest.
• The company's ability to raise capital through the newly approved share issuance will depend on market conditions and investor appetite, which could be challenging if the price is below market minimums.

Future Outlook

Kairos Pharma aims to enhance its public profile and engagement with the investment community through the new investor relations agreement. The approval for issuing additional common stock below minimum price suggests the company is positioning itself for potential future capital raises to support its operations or strategic initiatives.

Management Comments

• Dr. John S. Yu, Chief Executive Officer, signed the Services Agreement and the Form 8-K report on behalf of Kairos Pharma, Ltd., indicating management's commitment to the reported actions and agreements.

Industry Context

In the pharmaceutical and biotechnology sectors, companies, especially those in development stages, frequently engage investor relations firms to manage their public image, attract investment, and communicate progress to a specialized investor base. The approval of a dilutive share issuance mechanism is also common for growth-oriented companies seeking to fund research, development, or commercialization efforts.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution due to the approved share issuance below minimum price, but also potential for increased market visibility and investor interest through the new IR agreement.
• Employees: Stable management and governance structure maintained through director re-elections.
• Investment Community: Increased engagement and access to company information through Barretto Pacific Corporation's investor relations services.
• Creditors: No direct impact mentioned, but potential capital raise could affect the company's financial structure.

Next Steps

• Barretto Pacific Corporation will commence providing investor relations services to Kairos Pharma, Ltd. for a one-year term.
• Kairos Pharma will continue to make monthly payments to BPC as per the Services Agreement.
• The company may explore capital raising opportunities utilizing the newly approved authorization for share issuance below minimum price.
• The newly elected board of directors will serve for a term of one year until the next Annual Meeting.

Key Dates

Keywords

Kairos Pharma, KAPA, SEC filing, 8-K, investor relations, corporate governance, share issuance, stock dilution, annual meeting, NYSE American, pharma, biotechnology